Literature DB >> 1607530

Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.

F A Nicolini1, W W Nichols, J L Mehta, T G Saldeen, R Schofield, M Ross, D W Player, G B Pohl, C Mattsson.   

Abstract

Coronary artery reocclusion after thrombolysis with human recombinant tissue-type plasminogen activator (rt-PA) is related to the short half-life of this agent in plasma. K2P, a mutant of rt-PA lacking the fibronectin fingerlike, epidermal growth factor-like and first kringle domains (amino acids 6 to 173) and having the glycosylation site Asn184 mutagenized to Gln, has been produced in Chinese hamster ovary cells. In this study we compared the thrombolytic effect of K2P and rt-PA in dogs with electrically induced coronary artery thrombosis. Both agents were given intravenously in equimolar amounts over 20 min after the occlusive thrombus was stable for 30 min; dogs were monitored for 1 h after reperfusion if flow occurred. Coronary blood flow was restored by rt-PA in 6 (60%) of 10 dogs. The restored flow lasted for 49 +/- 12 min and mean flow at 60 min from the start of reperfusion was 7 +/- 3 ml/min. The reocclusion rate was 50% (three of six dogs). Flow was restored in five (100%) of five dogs by K2P. The restored blood flow lasted during the entire 1-h observation period in all but one dog and mean flow at 60 min was 49 +/- 16 ml/min (p less than 0.02 vs. flow in rt-PA-treated dogs). Restored coronary blood flow showed marked cyclic flow variations in rt-PA-treated but not in K2P-treated dogs.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607530     DOI: 10.1016/0735-1097(92)90164-i

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

Review 1.  Streptokinase--the drug of choice for thrombolytic therapy.

Authors:  Adinarayana Kunamneni; Thaer Taleb Abed Abdelghani; Poluri Ellaiah
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

2.  Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.

Authors:  H Matsuno; O Kozawa; S Nagashima; M Kanamaru; T Uematsu
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 3.  Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

4.  Effects of Recombinant Human Megakaryocyte Growth and Development Factor (rHuMGDF) on Platelet Production, Platelet Aggregation, and Thrombosis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

Review 5.  Thrombolytic agents in development.

Authors:  M Verstraete; H R Lijnen; D Collen
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 6.  Novel thrombolytic agents.

Authors:  M Verstraete; H R Lijnen
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

7.  Antithrombotic Effects of Five Organic Extracts of Bangladeshi Plants In Vitro and Mechanisms in In Silico Models.

Authors:  Sakib Mahmud; Samina Akhter; Md Atiar Rahman; Jannatul Aklima; Shaheen Akhter; Syeeda Rayhana Merry; S M Rakibul Jubair; Raju Dash; Talha Bin Emran
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-17       Impact factor: 2.629

8.  Evaluation of thrombolytic potential of three medicinal plants available in Bangladesh, as a potent source of thrombolytic compounds.

Authors:  Ali Ramjan; Marjan Hossain; Jannatul Ferdous Runa; Hasanuzzaman Md; Islam Mahmodul
Journal:  Avicenna J Phytomed       Date:  2014-11

9.  In vivo and in vitro evaluation of pharmacological activities of Adenia trilobata (Roxb.).

Authors:  Niloy Barua; Md Arfin Ibn Aziz; Abu Montakim Tareq; Mohammed Aktar Sayeed; Najmul Alam; Nobi Ul Alam; Mohammad Amran Uddin; Chadni Lyzu; Talha Bin Emran
Journal:  Biochem Biophys Rep       Date:  2020-06-09

10.  Effect of Fagonia Arabica (Dhamasa) on in vitro thrombolysis.

Authors:  Sweta Prasad; Rajpal Singh Kashyap; Jayant Y Deopujari; Hemant J Purohit; Girdhar M Taori; Hatim F Daginawala
Journal:  BMC Complement Altern Med       Date:  2007-11-06       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.